A Raman Imaging Approach Using CD47 Antibody-Labeled SERS Nanoparticles for Identifying Breast Cancer and Its Potential to Guide Surgical Resection
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Raman spectroscopic imaging has shown great promise for improved cancer detection and localization with the use of tumor targeting surface enhanced Raman scattering (SERS) nanoparticles. With the ultrasensitive detection and multiplexing capabilities that SERS imaging has to offer, scientists have been investigating several clinical applications that could benefit from this unique imaging strategy. Recently, there has been a push to develop new image-guidance tools for surgical resection to help surgeons sensitively and specifically identify tumor margins in real time. We hypothesized that SERS nanoparticles (NPs) topically applied to breast cancer resection margins have the potential to provide real-time feedback on the presence of residual cancer in the resection margins during lumpectomy. Here, we explore the ability of SERS nanoparticles conjugated with a cluster of differentiation-47 (CD47) antibody to target breast cancer. CD47 is a cell surface receptor that has recently been shown to be overexpressed on several solid tumor types. The binding potential of our CD47-labeled SERS nanoparticles was assessed using fluorescence assisted cell sorting (FACS) on seven different human breast cancer cell lines, some of which were triple negative (negative expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2)). Xenograft mouse models were also used to assess the ability of our Raman imaging system to identify tumor from normal tissue. A ratiometric imaging strategy was used to quantify specific vs. nonspecific probe binding, resulting in improved tumor-to-background ratios. FACS analysis showed that CD47-labeled SERS nanoparticles bound to seven different breast cancer cell lines at levels 12-fold to 70-fold higher than isotype control-labeled nanoparticles (p < 0.01), suggesting that our CD47-targeted nanoparticles actively bind to CD47 on breast cancer cells. In a mouse xenograft model of human breast cancer, topical application of CD47-targeted nanoparticles to excised normal and cancer tissue revealed increased binding of CD47-targeted nanoparticles on tumor relative to normal adjacent tissue. The findings of this study support further investigation and suggest that SERS nanoparticles topically applied to breast cancer could guide more complete surgical resection during lumpectomy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“With modern laser and sensor technology and the selective enhancement of SERS NP reporter molecules’ Raman scattering over any background intrinsic scattering, we can rapidly and quantitatively detect the spatial distribution of multiple SERS NP types, or flavors, in a single Raman hyperspectral image.10,13,14”
From Assessment of unmixing approaches for the quantitation of SERS nanoparticles in highly multiplexed spectral images (2024) · cites this paper as [14]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Stummer, W., Pichlmeier, U., Meinel, T., Wiestler, O. D., Zanella, F., & Reulen, H.-J. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70665-9 · Cited by 3,423 · cited 1×
“Several clinical trials supported its efficacy, revealing a more “complete” resection of tumor in patients as compared to the control arm [45,46].”
BackgroundBreast cancer statistics, 2013
DeSantis, C., Ma, J., Bryan, L., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21203 · Cited by 2,143
Bauer, K. R., Brown, M., Cress, R. D., Parise, C. A., & Caggiano, V. (2007) · Cancer · doi:10.1002/cncr.22618 · Cited by 2,067
Willingham, S. B., Volkmer, J.-P., Gentles, A. J., Sahoo, D., Dalerba, P., Mitra, S. S., Wang, J., Contreras-Trujillo, H., Martin, R., Cohen, J. D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121623109 · Cited by 1,666
AMIDE: A Free Software Tool for Multimodality Medical Image Analysis
Loening, A. M., & Gambhir, S. S. (2003) · Molecular Imaging · doi:10.1162/15353500200303133 · Cited by 1,018
Understanding Costs of Care in the Operating Room
Childers, C. P., & Maggard-Gibbons, M. (2018) · JAMA Surgery · doi:10.1001/jamasurg.2017.6233 · Cited by 923
Zavaleta, C. L., Smith, B. R., Walton, I., Doering, W., Davis, G., Shojaei, B., Natan, M. J., & Gambhir, S. S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813327106 · Cited by 714
Self-citationTrends in Breast Cancer by Race and Ethnicity: Update 2006
Smigal, C., Jemal, A., Ward, E., Cokkinides, V., Smith, R., Howe, H. L., & Thun, M. (2006) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.56.3.168 · Cited by 704
Bostwick, D. G., Pacelli, A., Blute, M., Roche, P., & Murphy, G. P. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980601)82:11<2256::aid-cncr22>3.0.co;2-s · Cited by 698
Cited by
Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis
Zhang, W., Huang, Q., Xiao, W., Zhao, Y., Pi, J., Xu, H., Zhao, H., Xu, J., Evans, C. E., & Jin, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00018 · Cited by 353
Cancer nanotechnology: current status and perspectives
Kemp, J. A., & Kwon, Y. J. (2021) · Nano Convergence · doi:10.1186/s40580-021-00282-7 · Cited by 266
Beeram, R., Vepa, K. R., & Soma, V. R. (2023) · Biosensors · doi:10.3390/bios13030328 · Cited by 174
Design and Synthesis of SERS Materials for In Vivo Molecular Imaging and Biosensing
Li, Q., Huo, H., Wu, Y., Chen, L., Su, L., Zhang, X., Song, J., & Yang, H. (2023) · Advanced Science · doi:10.1002/advs.202202051 · Cited by 170
Role of CD47 in Hematological Malignancies
Eladl, E., Tremblay-LeMay, R., Rastgoo, N., Musani, R., Chen, W., Liu, A., & Chang, H. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00930-1 · Cited by 160
“combined anti-CD47 antibodies with nanoparticles to target ovarian cancer cells [91].”
Background
Metadata
- Authors
- Davis, R. M., Campbell, J. L., Burkitt, S., Qiu, Z., Kang, S., Mehraein, M., Miyasato, D., Salinas, H., Liu, J. T. C., & Zavaleta, C.
- Affiliations
- Stanford Medicine (US)
- University of Southern California (US)
- Michigan State University (US)
- University of Washington (US)
- Corresponding author
- Zavaleta, Cristina
- ORCID
- Venue
- Nanomaterials
- Publisher
- MDPI AG
- Published
- 2018-11-20
- Volume
- 8
- Issue
- 11
- Pages
- 953
- ISSN
- 2079-4991 (ISSN-L)
- PMC
- PMC6265869
- OpenAlex
- W2901440549
- Cited by
- 60
- References
- 58
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 12 · 2023: 5 · 2022: 9 · 2021: 12 · 2020: 8 · 2019: 5
- FWCI
- 3.26
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Nanomaterials (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Foundation for the National Institutes of Health (R21CA184608, K22CA160834)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biophysics › Spectroscopy Techniques in Biomedical and Chemical Research
- Physical Sciences › Materials Science › Electronic, Optical and Magnetic Materials › Gold and Silver Nanoparticles Synthesis and Applications
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Keywords
- breast cancer, CD47, Raman imaging, image-guided surgery, surgical resection margin, breast-conserving surgery, tumor targeting, ratiometric imaging, triple-negative breast cancer, xenograft mouse model
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Raman Imaging Approach Using CD47 Antibody-Labeled SERS Nanoparticles for Identifying Breast Cancer and Its Potential to Guide Surgical Resection. https://app.cochat.ai/papers/10.3390/nano8110953
- The paper
- Davis, R. M., Campbell, J. L., Burkitt, S., Qiu, Z., Kang, S., Mehraein, M., Miyasato, D., Salinas, H., Liu, J. T. C., & Zavaleta, C. (2018). A Raman Imaging Approach Using CD47 Antibody-Labeled SERS Nanoparticles for Identifying Breast Cancer and Its Potential to Guide Surgical Resection. Nanomaterials. https://doi.org/10.3390/nano8110953
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.